Want to see IDYA full AI Analyst Report?
Top Page
IDEAYA Biosciences
(NASDAQ:IDYA)
Select Model
Select Model
Rating:60Neutral
Price Target:
$42.00
▲(0.55% Upside)
Action:Reiterated
Date:08/05/26
The score is driven primarily by strong balance-sheet strength and improving revenue momentum, supported by constructive (but not strong) technicals. Offsetting factors are the company’s continued large losses and ongoing free-cash-flow burn, while valuation is less attractive due to negative earnings despite favorable corporate/clinical catalysts.
Positive Factors
Strong balance sheet
Very low leverage gives IDEAYA substantial financial flexibility to continue funding research and development while absorbing biotech-sector volatility. The large equity and asset base reduces reliance on debt financing and provides a stronger foundation for advancing its clinical pipeline.
Negative Factors
Persistent unprofitability
IDEAYA remains far from break-even despite strong revenue growth, with substantial losses consuming capital and preventing current earnings from self-funding development. Sustained negative margins could require continued external financing and delay the point at which pipeline success translates into durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Very low leverage gives IDEAYA substantial financial flexibility to continue funding research and development while absorbing biotech-sector volatility. The large equity and asset base reduces reliance on debt financing and provides a stronger foundation for advancing its clinical pipeline.
Read all positive factors
IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.60B
Dividend YieldN/A
Average Volume (3M)808.13K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth3244.67%
EPS Growth49.14%
CountryUS
Employees145
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.92
Shares Outstanding96,489,490
10 Day Avg. Volume1,140,607
30 Day Avg. Volume808,129
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue11.24
Enterprise Value/Gross Profit-84.37
Enterprise Value/Ebitda-12.39
Forecast
1Y Price Target
$54.44Price Target Upside30.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.59
Revenue Forecast (FY)$38.36M
IDEAYA Biosciences Business Overview & Revenue Model
Company Description
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient grou...
How the Company Makes Money
IDEAYA makes money primarily through (1) collaboration and partnership revenue and (2) other operating income typical of a clinical-stage biotech (e.g., interest income on cash and investments). Collaboration revenue is generated when IDEAYA enter...
IDEAYA Biosciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
76
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 234.13M | 218.71M | 7.00M | 23.39M | 50.93M | 27.94M |
| Gross Profit | -31.19M | -95.99M | 3.17M | 19.38M | 48.83M | 26.22M |
| EBITDA | -212.46M | -154.72M | -270.64M | -108.95M | -56.55M | -48.04M |
| Net Income | -175.02M | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
Balance Sheet | ||||||
| Total Assets | 1.31B | 1.11B | 1.12B | 649.32M | 387.97M | 381.35M |
| Cash, Cash Equivalents and Short-Term Investments | 828.96M | 639.39M | 676.32M | 525.11M | 364.83M | 246.77M |
| Total Debt | 29.31M | 27.91M | 19.17M | 2.87M | 3.48M | 5.18M |
| Total Liabilities | 110.79M | 86.39M | 64.94M | 28.23M | 38.51M | 79.83M |
| Stockholders Equity | 1.20B | 1.02B | 1.06B | 621.09M | 349.45M | 301.51M |
Cash Flow | ||||||
| Free Cash Flow | -113.87M | -73.47M | -251.44M | -117.59M | -90.62M | -58.42M |
| Operating Cash Flow | -111.66M | -71.10M | -247.58M | -115.22M | -87.17M | -55.78M |
| Investing Cash Flow | -92.74M | 69.98M | -502.56M | -158.46M | -33.40M | -69.67M |
| Financing Cash Flow | 362.82M | 29.78M | 677.55M | 362.72M | 97.17M | 145.45M |
IDEAYA Biosciences Technical Analysis
Negative
41.77
Price Trends
38.00
Negative
35.30
Positive
34.07
Positive
Market Momentum
-0.19
Positive
45.41
Neutral
51.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Negative. The current price of 41.77 is above the 20-day moving average (MA) of 38.08, above the 50-day MA of 38.00, and above the 200-day MA of 34.07, indicating a neutral trend. The MACD of -0.19 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 51.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDYA.
IDEAYA Biosciences Risk Analysis
IDEAYA Biosciences disclosed 76 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IDEAYA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.60B | -19.46 | -16.47% | ― | 3244.67% | 49.14% | |
58 Neutral | $947.43M | -3.16 | -207.18% | ― | -7.27% | -48.89% | |
55 Neutral | $4.15B | -12.08 | -42.27% | ― | 23.86% | 19.60% | |
54 Neutral | $1.81B | -11.83 | -49.73% | ― | 1083.56% | 30.89% | |
52 Neutral | $5.16B | -15.52 | -80.43% | ― | ― | -110.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $3.92B | -27.34 | -25.74% | ― | 121.47% | 36.95% |
* Healthcare Sector Average
IDYA
IDEAYA Biosciences
37.36
9.87
35.90%
KURA
Kura Oncology
10.65
0.85
8.67%
RLAY
Relay Therapeutics
18.96
13.37
239.18%
TNGX
Tango Therapeutics
23.24
15.66
206.60%
NUVB
Nuvation Bio
5.14
1.37
36.34%
ERAS
Erasca
14.74
12.41
532.62%
IDEAYA Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes
Positive
Jun 23, 2026
On June 16, 2026, IDEAYA Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where investors voted on the election of three Class I directors, ratification of the company’s independent auditor for the 2026 fiscal year, and a non-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.